 Nicholas Cost
Concepts (372)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 55 | 2024 | 334 | 16.170 |
Why?
| | Wilms Tumor | 29 | 2024 | 69 | 10.570 |
Why?
| | Testicular Neoplasms | 23 | 2023 | 97 | 9.790 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 14 | 2023 | 62 | 6.480 |
Why?
| | Nephrectomy | 31 | 2023 | 149 | 6.370 |
Why?
| | Carcinoma, Renal Cell | 17 | 2023 | 173 | 4.200 |
Why?
| | Lymph Node Excision | 12 | 2023 | 142 | 3.520 |
Why?
| | Rhabdoid Tumor | 5 | 2023 | 80 | 2.950 |
Why?
| | Lymph Nodes | 9 | 2023 | 425 | 2.820 |
Why?
| | Neoplasm Staging | 25 | 2023 | 1180 | 2.690 |
Why?
| | Medical Oncology | 7 | 2023 | 228 | 2.420 |
Why?
| | Child | 81 | 2024 | 18362 | 2.200 |
Why?
| | Child, Preschool | 60 | 2023 | 9083 | 2.150 |
Why?
| | Orchiectomy | 8 | 2023 | 57 | 2.140 |
Why?
| | Laparoscopy | 11 | 2018 | 389 | 2.130 |
Why?
| | Rhabdomyosarcoma | 5 | 2022 | 55 | 1.990 |
Why?
| | Hydronephrosis | 6 | 2019 | 28 | 1.960 |
Why?
| | Adolescent | 64 | 2023 | 17826 | 1.940 |
Why?
| | Infant | 50 | 2023 | 7936 | 1.790 |
Why?
| | Lymphatic Metastasis | 12 | 2022 | 281 | 1.780 |
Why?
| | Urologic Surgical Procedures | 8 | 2019 | 94 | 1.740 |
Why?
| | Urologists | 3 | 2017 | 17 | 1.690 |
Why?
| | Urology | 7 | 2023 | 46 | 1.660 |
Why?
| | Urologic Neoplasms | 4 | 2017 | 25 | 1.610 |
Why?
| | Urinary Bladder | 4 | 2022 | 164 | 1.570 |
Why?
| | Male | 94 | 2023 | 55655 | 1.530 |
Why?
| | Kidney Pelvis | 6 | 2015 | 20 | 1.510 |
Why?
| | Robotics | 6 | 2015 | 75 | 1.510 |
Why?
| | Humans | 137 | 2024 | 114925 | 1.500 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2022 | 81 | 1.500 |
Why?
| | Urinary Bladder Neoplasms | 4 | 2021 | 196 | 1.360 |
Why?
| | Lower Urinary Tract Symptoms | 2 | 2021 | 48 | 1.330 |
Why?
| | Doxorubicin | 2 | 2021 | 286 | 1.290 |
Why?
| | Organ Sparing Treatments | 4 | 2023 | 31 | 1.280 |
Why?
| | Kidney | 9 | 2023 | 1184 | 1.250 |
Why?
| | Ureteral Obstruction | 5 | 2015 | 54 | 1.200 |
Why?
| | Urodynamics | 3 | 2019 | 28 | 1.170 |
Why?
| | Prognosis | 18 | 2023 | 3344 | 1.170 |
Why?
| | Urinary Bladder Diseases | 2 | 2019 | 19 | 1.170 |
Why?
| | Pediatrics | 5 | 2019 | 984 | 1.160 |
Why?
| | Retrospective Studies | 43 | 2023 | 12543 | 1.160 |
Why?
| | Tumor Burden | 6 | 2019 | 262 | 1.070 |
Why?
| | Young Adult | 31 | 2023 | 10476 | 1.060 |
Why?
| | Female | 71 | 2023 | 59571 | 1.040 |
Why?
| | Kidney Diseases, Cystic | 3 | 2021 | 21 | 0.990 |
Why?
| | Rhabdomyosarcoma, Embryonal | 2 | 2022 | 16 | 0.980 |
Why?
| | Nephrons | 9 | 2023 | 16 | 0.960 |
Why?
| | Vincristine | 2 | 2022 | 100 | 0.940 |
Why?
| | Urinary Tract | 2 | 2023 | 36 | 0.940 |
Why?
| | Practice Patterns, Physicians' | 5 | 2019 | 1177 | 0.930 |
Why?
| | Ribonuclease III | 3 | 2021 | 34 | 0.920 |
Why?
| | Mixed Tumor, Malignant | 1 | 2023 | 4 | 0.910 |
Why?
| | DEAD-box RNA Helicases | 3 | 2021 | 56 | 0.910 |
Why?
| | Biopsy | 5 | 2019 | 1045 | 0.890 |
Why?
| | Sertoli-Leydig Cell Tumor | 3 | 2021 | 8 | 0.890 |
Why?
| | Hypospadias | 4 | 2011 | 26 | 0.860 |
Why?
| | Seminoma | 3 | 2021 | 17 | 0.860 |
Why?
| | Sarcoma, Clear Cell | 2 | 2023 | 8 | 0.850 |
Why?
| | Urologic Surgical Procedures, Male | 4 | 2018 | 27 | 0.830 |
Why?
| | Sarcoma | 2 | 2022 | 138 | 0.830 |
Why?
| | Spermatic Cord Torsion | 2 | 2013 | 3 | 0.820 |
Why?
| | Leydig Cell Tumor | 3 | 2021 | 8 | 0.820 |
Why?
| | Disease-Free Survival | 7 | 2022 | 623 | 0.800 |
Why?
| | Paraganglioma | 1 | 2022 | 47 | 0.780 |
Why?
| | Age Factors | 12 | 2019 | 2891 | 0.780 |
Why?
| | Cryptorchidism | 2 | 2019 | 12 | 0.780 |
Why?
| | Tomography, X-Ray Computed | 9 | 2021 | 2326 | 0.770 |
Why?
| | Pulmonary Blastoma | 1 | 2021 | 8 | 0.750 |
Why?
| | Infant, Newborn | 11 | 2023 | 5035 | 0.750 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 121 | 0.740 |
Why?
| | Pheochromocytoma | 2 | 2019 | 54 | 0.730 |
Why?
| | Surgeons | 3 | 2023 | 237 | 0.730 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2019 | 5 | 0.690 |
Why?
| | Neoplasm Invasiveness | 7 | 2017 | 445 | 0.670 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 2 | 2017 | 5 | 0.670 |
Why?
| | Cystectomy | 1 | 2019 | 32 | 0.670 |
Why?
| | Molecular Targeted Therapy | 2 | 2013 | 347 | 0.670 |
Why?
| | Smooth Muscle Myosins | 1 | 2019 | 7 | 0.660 |
Why?
| | Muscle Relaxation | 1 | 2019 | 28 | 0.660 |
Why?
| | Myosin Light Chains | 1 | 2019 | 26 | 0.660 |
Why?
| | Neoadjuvant Therapy | 4 | 2021 | 305 | 0.650 |
Why?
| | Treatment Outcome | 25 | 2022 | 9105 | 0.650 |
Why?
| | Diagnostic Imaging | 3 | 2022 | 290 | 0.640 |
Why?
| | Radiotherapy | 1 | 2019 | 176 | 0.630 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2019 | 109 | 0.630 |
Why?
| | Specimen Handling | 1 | 2019 | 156 | 0.620 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2018 | 51 | 0.620 |
Why?
| | Catheterization | 1 | 2019 | 160 | 0.620 |
Why?
| | von Hippel-Lindau Disease | 1 | 2018 | 12 | 0.610 |
Why?
| | Testicular Diseases | 1 | 2018 | 6 | 0.610 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2019 | 863 | 0.610 |
Why?
| | Health Care Surveys | 2 | 2017 | 539 | 0.610 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2012 | 447 | 0.600 |
Why?
| | Calculi | 1 | 2018 | 16 | 0.590 |
Why?
| | Conservative Treatment | 1 | 2018 | 29 | 0.590 |
Why?
| | Orchiopexy | 3 | 2019 | 5 | 0.590 |
Why?
| | Cancer Survivors | 1 | 2021 | 205 | 0.580 |
Why?
| | Kaplan-Meier Estimate | 6 | 2019 | 817 | 0.580 |
Why?
| | Radiation Exposure | 1 | 2017 | 40 | 0.580 |
Why?
| | Critical Pathways | 1 | 2018 | 74 | 0.580 |
Why?
| | Risk Assessment | 10 | 2018 | 2975 | 0.580 |
Why?
| | Surveys and Questionnaires | 3 | 2018 | 4634 | 0.570 |
Why?
| | Lung Neoplasms | 3 | 2021 | 2222 | 0.570 |
Why?
| | Frozen Sections | 1 | 2017 | 24 | 0.560 |
Why?
| | Kidney Medulla | 1 | 2016 | 29 | 0.560 |
Why?
| | Cytodiagnosis | 1 | 2017 | 29 | 0.560 |
Why?
| | Surgical Oncology | 1 | 2016 | 18 | 0.550 |
Why?
| | Angiomyolipoma | 1 | 2016 | 17 | 0.550 |
Why?
| | Postoperative Care | 1 | 2018 | 220 | 0.550 |
Why?
| | Teratoma | 2 | 2017 | 92 | 0.550 |
Why?
| | Robotic Surgical Procedures | 2 | 2015 | 86 | 0.540 |
Why?
| | Neoplasms | 4 | 2023 | 2106 | 0.540 |
Why?
| | Tuberous Sclerosis | 1 | 2016 | 36 | 0.540 |
Why?
| | Muscle Contraction | 1 | 2019 | 399 | 0.530 |
Why?
| | Adult | 22 | 2020 | 30604 | 0.520 |
Why?
| | Granuloma, Plasma Cell | 1 | 2015 | 12 | 0.520 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1361 | 0.520 |
Why?
| | Glomerular Filtration Rate | 4 | 2018 | 604 | 0.510 |
Why?
| | Survival Analysis | 5 | 2019 | 1220 | 0.500 |
Why?
| | Pediatricians | 1 | 2016 | 122 | 0.490 |
Why?
| | Adenoma | 1 | 2016 | 189 | 0.490 |
Why?
| | Neurofibromatosis 1 | 2 | 2019 | 36 | 0.480 |
Why?
| | Hypertension | 1 | 2022 | 1059 | 0.470 |
Why?
| | Cause of Death | 1 | 2016 | 363 | 0.470 |
Why?
| | Ovarian Neoplasms | 3 | 2021 | 388 | 0.470 |
Why?
| | Prostatic Neoplasms | 2 | 2019 | 925 | 0.470 |
Why?
| | Pelvic Neoplasms | 2 | 2013 | 18 | 0.470 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2012 | 1893 | 0.470 |
Why?
| | Databases, Factual | 5 | 2019 | 1125 | 0.470 |
Why?
| | Ultrasonography | 5 | 2019 | 633 | 0.450 |
Why?
| | Societies, Medical | 4 | 2018 | 677 | 0.440 |
Why?
| | Acute-Phase Proteins | 1 | 2013 | 64 | 0.440 |
Why?
| | Lipocalins | 1 | 2013 | 35 | 0.440 |
Why?
| | Patient Education as Topic | 1 | 2018 | 678 | 0.430 |
Why?
| | SEER Program | 5 | 2019 | 196 | 0.430 |
Why?
| | Radiation Protection | 1 | 2013 | 34 | 0.420 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2013 | 66 | 0.420 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2016 | 400 | 0.420 |
Why?
| | Fertility Preservation | 2 | 2023 | 46 | 0.410 |
Why?
| | Biopsy, Needle | 1 | 2013 | 183 | 0.410 |
Why?
| | Multimodal Imaging | 1 | 2013 | 92 | 0.410 |
Why?
| | Retroperitoneal Space | 1 | 2012 | 15 | 0.400 |
Why?
| | Incidence | 7 | 2019 | 2316 | 0.400 |
Why?
| | Glucose Transporter Type 1 | 1 | 2012 | 42 | 0.400 |
Why?
| | Neoplasm Metastasis | 5 | 2019 | 530 | 0.400 |
Why?
| | Follow-Up Studies | 11 | 2019 | 4427 | 0.390 |
Why?
| | United States | 12 | 2021 | 12209 | 0.390 |
Why?
| | Survival Rate | 6 | 2024 | 1644 | 0.390 |
Why?
| | Primary Prevention | 1 | 2013 | 171 | 0.380 |
Why?
| | Positron-Emission Tomography | 1 | 2013 | 265 | 0.380 |
Why?
| | Multivariate Analysis | 5 | 2018 | 1440 | 0.380 |
Why?
| | Codon | 1 | 2011 | 86 | 0.370 |
Why?
| | Proline | 1 | 2011 | 72 | 0.370 |
Why?
| | Seasons | 1 | 2013 | 448 | 0.360 |
Why?
| | Combined Modality Therapy | 4 | 2023 | 1126 | 0.360 |
Why?
| | Vena Cava, Inferior | 1 | 2011 | 56 | 0.360 |
Why?
| | Breast Neoplasms | 1 | 2022 | 1870 | 0.360 |
Why?
| | Suburethral Slings | 1 | 2010 | 4 | 0.360 |
Why?
| | Temperature | 1 | 2013 | 576 | 0.360 |
Why?
| | Arginine | 1 | 2011 | 237 | 0.350 |
Why?
| | Prospective Studies | 8 | 2021 | 6218 | 0.350 |
Why?
| | Hernia, Ventral | 1 | 2010 | 18 | 0.340 |
Why?
| | Urinary Bladder, Neurogenic | 1 | 2010 | 30 | 0.340 |
Why?
| | Urinary Incontinence | 1 | 2010 | 56 | 0.340 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 611 | 0.340 |
Why?
| | Attitude of Health Personnel | 1 | 2016 | 978 | 0.340 |
Why?
| | Recovery of Function | 1 | 2013 | 572 | 0.330 |
Why?
| | Mouth Mucosa | 1 | 2009 | 79 | 0.330 |
Why?
| | Skin Transplantation | 1 | 2009 | 57 | 0.330 |
Why?
| | Ureter | 4 | 2014 | 31 | 0.330 |
Why?
| | Bone Neoplasms | 1 | 2011 | 194 | 0.330 |
Why?
| | Campomelic Dysplasia | 1 | 2009 | 2 | 0.330 |
Why?
| | Dysgerminoma | 1 | 2009 | 3 | 0.330 |
Why?
| | Venous Thrombosis | 1 | 2011 | 142 | 0.330 |
Why?
| | Angiogenesis Inhibitors | 1 | 2011 | 215 | 0.330 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 638 | 0.330 |
Why?
| | Urethra | 2 | 2011 | 48 | 0.330 |
Why?
| | Urolithiasis | 1 | 2009 | 8 | 0.330 |
Why?
| | Brachytherapy | 2 | 2021 | 104 | 0.320 |
Why?
| | Clitoris | 1 | 2009 | 8 | 0.320 |
Why?
| | SOX9 Transcription Factor | 1 | 2009 | 23 | 0.320 |
Why?
| | Aged | 11 | 2021 | 19120 | 0.320 |
Why?
| | Time Factors | 8 | 2019 | 6125 | 0.320 |
Why?
| | Surgical Flaps | 1 | 2009 | 121 | 0.310 |
Why?
| | Middle Aged | 12 | 2021 | 26801 | 0.300 |
Why?
| | Risk Factors | 8 | 2018 | 8637 | 0.290 |
Why?
| | Health Promotion | 1 | 2013 | 686 | 0.280 |
Why?
| | Calcinosis | 1 | 2009 | 242 | 0.270 |
Why?
| | Ureterocele | 2 | 2016 | 7 | 0.250 |
Why?
| | Vesico-Ureteral Reflux | 2 | 2016 | 22 | 0.250 |
Why?
| | Kidney Diseases | 1 | 2009 | 350 | 0.250 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 796 | 0.250 |
Why?
| | Mitotic Index | 2 | 2015 | 26 | 0.250 |
Why?
| | Hypertrophy | 2 | 2019 | 111 | 0.240 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2013 | 333 | 0.230 |
Why?
| | Gonadal Dysgenesis | 1 | 2023 | 8 | 0.220 |
Why?
| | Minimally Invasive Surgical Procedures | 3 | 2014 | 153 | 0.220 |
Why?
| | Germ-Line Mutation | 2 | 2021 | 131 | 0.210 |
Why?
| | Algorithms | 1 | 2009 | 1474 | 0.210 |
Why?
| | Pubic Bone | 1 | 2022 | 4 | 0.210 |
Why?
| | Sex Factors | 2 | 2017 | 1721 | 0.200 |
Why?
| | Urination | 1 | 2022 | 41 | 0.200 |
Why?
| | Infertility | 1 | 2022 | 45 | 0.200 |
Why?
| | Testosterone | 2 | 2015 | 343 | 0.190 |
Why?
| | Sertoli Cell Tumor | 1 | 2021 | 2 | 0.190 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2022 | 100 | 0.190 |
Why?
| | Reoperation | 3 | 2014 | 515 | 0.190 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2021 | 22 | 0.190 |
Why?
| | Diagnosis, Differential | 3 | 2019 | 1355 | 0.190 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2019 | 66 | 0.190 |
Why?
| | Aniridia | 1 | 2020 | 5 | 0.190 |
Why?
| | PAX6 Transcription Factor | 1 | 2020 | 19 | 0.180 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2021 | 29 | 0.180 |
Why?
| | Codon, Nonsense | 1 | 2020 | 37 | 0.180 |
Why?
| | Interleukin-2 | 1 | 2022 | 419 | 0.180 |
Why?
| | Pneumothorax | 1 | 2021 | 41 | 0.180 |
Why?
| | Eye Proteins | 1 | 2020 | 71 | 0.180 |
Why?
| | Genetic Predisposition to Disease | 3 | 2021 | 2102 | 0.180 |
Why?
| | Patient Selection | 3 | 2013 | 642 | 0.170 |
Why?
| | Syndrome | 1 | 2021 | 336 | 0.170 |
Why?
| | Penile Neoplasms | 1 | 2019 | 7 | 0.170 |
Why?
| | Priapism | 1 | 2019 | 10 | 0.170 |
Why?
| | Proportional Hazards Models | 3 | 2011 | 1080 | 0.170 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2019 | 40 | 0.170 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2019 | 9 | 0.170 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 1 | 2019 | 9 | 0.170 |
Why?
| | Myosin-Light-Chain Kinase | 1 | 2019 | 19 | 0.170 |
Why?
| | Decision Trees | 1 | 2019 | 80 | 0.160 |
Why?
| | Genotype | 2 | 2016 | 1775 | 0.160 |
Why?
| | Computers | 1 | 2019 | 60 | 0.160 |
Why?
| | Hospitals | 1 | 2023 | 581 | 0.160 |
Why?
| | Genetic Testing | 2 | 2019 | 379 | 0.160 |
Why?
| | Puberty, Precocious | 1 | 2019 | 13 | 0.160 |
Why?
| | Aged, 80 and over | 4 | 2019 | 6363 | 0.160 |
Why?
| | Dermatofibrosarcoma | 1 | 2018 | 9 | 0.160 |
Why?
| | Diagnostic Errors | 1 | 2019 | 151 | 0.160 |
Why?
| | Mutation | 1 | 2009 | 3353 | 0.150 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 190 | 0.150 |
Why?
| | Self-Examination | 1 | 2018 | 1 | 0.150 |
Why?
| | General Surgery | 1 | 2019 | 126 | 0.150 |
Why?
| | Proton Therapy | 1 | 2018 | 10 | 0.150 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 126 | 0.150 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2018 | 182 | 0.150 |
Why?
| | Preoperative Period | 1 | 2018 | 103 | 0.150 |
Why?
| | Feasibility Studies | 2 | 2018 | 737 | 0.150 |
Why?
| | Asymptomatic Diseases | 1 | 2018 | 75 | 0.150 |
Why?
| | Carcinoma, Medullary | 1 | 2017 | 13 | 0.150 |
Why?
| | Postoperative Complications | 4 | 2023 | 2132 | 0.150 |
Why?
| | Drug Utilization | 1 | 2018 | 167 | 0.140 |
Why?
| | Ultrasonography, Doppler | 1 | 2018 | 104 | 0.140 |
Why?
| | Analysis of Variance | 2 | 2017 | 1227 | 0.140 |
Why?
| | Unnecessary Procedures | 1 | 2017 | 43 | 0.140 |
Why?
| | Testis | 1 | 2018 | 133 | 0.140 |
Why?
| | Europe | 1 | 2018 | 336 | 0.140 |
Why?
| | Intraoperative Period | 1 | 2017 | 50 | 0.140 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 227 | 0.140 |
Why?
| | Logistic Models | 3 | 2018 | 1843 | 0.140 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 337 | 0.140 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1152 | 0.130 |
Why?
| | Length of Stay | 2 | 2018 | 949 | 0.130 |
Why?
| | Certification | 1 | 2016 | 89 | 0.130 |
Why?
| | Antineoplastic Agents | 2 | 2018 | 1897 | 0.130 |
Why?
| | North America | 1 | 2016 | 257 | 0.130 |
Why?
| | Feminization | 1 | 2015 | 6 | 0.130 |
Why?
| | Translocation, Genetic | 2 | 2018 | 94 | 0.130 |
Why?
| | Models, Statistical | 1 | 2019 | 604 | 0.130 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1400 | 0.130 |
Why?
| | Learning | 1 | 2019 | 352 | 0.120 |
Why?
| | History, 21st Century | 1 | 2015 | 161 | 0.120 |
Why?
| | Phosphorylation | 1 | 2019 | 1572 | 0.120 |
Why?
| | Registries | 2 | 2019 | 1760 | 0.120 |
Why?
| | Forecasting | 1 | 2016 | 333 | 0.120 |
Why?
| | Matched-Pair Analysis | 1 | 2014 | 33 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 3 | 2021 | 3053 | 0.120 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2014 | 18 | 0.120 |
Why?
| | Genitalia, Female | 1 | 2014 | 37 | 0.110 |
Why?
| | Ureteral Calculi | 1 | 2014 | 13 | 0.110 |
Why?
| | TRPM Cation Channels | 1 | 2014 | 67 | 0.110 |
Why?
| | Kidney Function Tests | 1 | 2014 | 140 | 0.110 |
Why?
| | Disease Management | 1 | 2017 | 563 | 0.110 |
Why?
| | Lipocalin-2 | 1 | 2013 | 62 | 0.110 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 387 | 0.110 |
Why?
| | Estrogens | 1 | 2015 | 312 | 0.110 |
Why?
| | Cohort Studies | 5 | 2016 | 4903 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2020 | 834 | 0.110 |
Why?
| | Biomarkers, Tumor | 2 | 2021 | 1054 | 0.100 |
Why?
| | Creatinine | 1 | 2014 | 424 | 0.100 |
Why?
| | Autophagy | 1 | 2014 | 234 | 0.100 |
Why?
| | Blood Vessels | 1 | 2014 | 180 | 0.100 |
Why?
| | Tissue Array Analysis | 1 | 2012 | 50 | 0.100 |
Why?
| | Spermatic Cord | 1 | 2012 | 1 | 0.100 |
Why?
| | Cross-Sectional Studies | 2 | 2014 | 4406 | 0.100 |
Why?
| | Monitoring, Physiologic | 1 | 2014 | 248 | 0.100 |
Why?
| | Fetal Diseases | 1 | 2013 | 147 | 0.100 |
Why?
| | Radiation Dosage | 1 | 2013 | 136 | 0.100 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 195 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2018 | 762 | 0.100 |
Why?
| | Animals | 4 | 2022 | 31837 | 0.090 |
Why?
| | Referral and Consultation | 1 | 2016 | 634 | 0.090 |
Why?
| | Surgical Wound Dehiscence | 1 | 2011 | 19 | 0.090 |
Why?
| | Clinical Competence | 1 | 2017 | 901 | 0.090 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2011 | 54 | 0.090 |
Why?
| | Thrombectomy | 1 | 2011 | 52 | 0.090 |
Why?
| | Bevacizumab | 1 | 2011 | 115 | 0.090 |
Why?
| | Texas | 1 | 2011 | 188 | 0.090 |
Why?
| | Sulfonamides | 1 | 2014 | 445 | 0.090 |
Why?
| | Internship and Residency | 1 | 2019 | 944 | 0.090 |
Why?
| | Rectum | 1 | 2011 | 153 | 0.090 |
Why?
| | Compliance | 1 | 2010 | 46 | 0.090 |
Why?
| | Pyrroles | 1 | 2011 | 183 | 0.090 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 495 | 0.090 |
Why?
| | Operative Time | 3 | 2014 | 106 | 0.080 |
Why?
| | Pilot Projects | 1 | 2014 | 1372 | 0.080 |
Why?
| | Muscle, Smooth | 1 | 2010 | 147 | 0.080 |
Why?
| | Penis | 2 | 2019 | 37 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 995 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 718 | 0.080 |
Why?
| | Indoles | 1 | 2011 | 306 | 0.080 |
Why?
| | Alleles | 1 | 2011 | 791 | 0.080 |
Why?
| | MicroRNAs | 1 | 2014 | 601 | 0.080 |
Why?
| | Radiography | 1 | 2011 | 819 | 0.080 |
Why?
| | Remission, Spontaneous | 2 | 2021 | 37 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1801 | 0.070 |
Why?
| | Congenital Abnormalities | 1 | 2008 | 73 | 0.070 |
Why?
| | Biomarkers | 2 | 2019 | 3418 | 0.070 |
Why?
| | Mice | 2 | 2022 | 14935 | 0.070 |
Why?
| | Kidney Failure, Chronic | 1 | 2012 | 488 | 0.070 |
Why?
| | Pregnancy | 1 | 2018 | 5525 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2014 | 3008 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2542 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 666 | 0.070 |
Why?
| | Signal Transduction | 1 | 2019 | 4524 | 0.070 |
Why?
| | Cystoscopy | 2 | 2016 | 16 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1270 | 0.060 |
Why?
| | Anaplasia | 1 | 2024 | 2 | 0.060 |
Why?
| | Nephroureterectomy | 1 | 2023 | 2 | 0.060 |
Why?
| | Sexual Development | 1 | 2023 | 19 | 0.050 |
Why?
| | Gonads | 1 | 2023 | 21 | 0.050 |
Why?
| | Germany | 1 | 2020 | 84 | 0.040 |
Why?
| | Accreditation | 1 | 2019 | 78 | 0.040 |
Why?
| | Hyperplasia | 1 | 2019 | 164 | 0.040 |
Why?
| | Mohs Surgery | 1 | 2018 | 25 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2018 | 24 | 0.040 |
Why?
| | Perioperative Care | 1 | 2019 | 126 | 0.040 |
Why?
| | Mosaicism | 1 | 2017 | 61 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2018 | 314 | 0.040 |
Why?
| | Ureteroscopy | 1 | 2016 | 16 | 0.030 |
Why?
| | Monitoring, Intraoperative | 1 | 2016 | 39 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 374 | 0.030 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2014 | 11 | 0.030 |
Why?
| | Caveolin 1 | 1 | 2014 | 20 | 0.030 |
Why?
| | Ureterostomy | 1 | 2014 | 3 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 232 | 0.030 |
Why?
| | Oncogenes | 1 | 2014 | 108 | 0.030 |
Why?
| | Cicatrix | 1 | 2014 | 50 | 0.030 |
Why?
| | Bone Marrow Neoplasms | 1 | 2013 | 3 | 0.030 |
Why?
| | Organ Size | 1 | 2014 | 435 | 0.030 |
Why?
| | Mice, Nude | 1 | 2014 | 635 | 0.030 |
Why?
| | RNA Interference | 1 | 2014 | 437 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2014 | 591 | 0.030 |
Why?
| | Pain, Postoperative | 1 | 2013 | 191 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2359 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2011 | 28 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1700 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2011 | 243 | 0.020 |
Why?
| | Area Under Curve | 1 | 2011 | 275 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 317 | 0.020 |
Why?
| | Gene Silencing | 1 | 2011 | 172 | 0.020 |
Why?
| | Dihydrolipoamide Dehydrogenase | 1 | 2009 | 7 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1148 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 2725 | 0.020 |
Why?
| | Analgesics, Opioid | 1 | 2013 | 773 | 0.020 |
Why?
|
|
Cost's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|